Cardiovascular Outcomes of SGLT-2i vs Other Glucose-Lowering Drugs in T2D
A recent study evaluated the effects of SGLT-2i and other glucose-lowering drugs on cardiovascular event outcomes in patients with type 2 diabetes from 6 countries in 3 world regions.